News
Liquidia Technologies Inc. Studies Show PRINT® Engineered Particles Hold Promise in the Delivery of Respiratory Therapeutics
BioSpace
May 15, 2012
Liquidia Founder Dr. Joseph DeSimone Elected into National Academy of Sciences
CityBizList
May 3, 2012
Liquidia figuring out how to ‘unleash’ technology
The Herald-Sun
April 6, 2012
Liquidia CEO to Participate in Biotech Panel to Explore “How to Create 54 Liquidias”
Business Wire
April 3, 2012
Big business appeal of nanotechnology on display in Durham
WRAL Tech Wire
April 2, 2012
Liquidia Technologies
Research Triangle Park, NC
Liquidia utilizes a proprietary technology platform to design and manufacture highly precise nanoparticles that allow for the delivery of biological and small molecule vaccines and therapeutics. The company’s technology makes it possible for the first time to design vaccines and therapies with precise control of particle size, shape, and composition.